Literature DB >> 178468

Evidence that des-Asp1 angiotensin II mediates the renin-angiotensin response.

R H Freeman, J O Davis, T E Lohmeier, W S Spielman.   

Abstract

Studies were undertaken to compare and evaluate the influence of angiotensin II and its heptapeptide fragments, des-Asp-1-angiotensin II, at various receptor sites for angiotensin in both dogs and rats. Receptor sites evaluated were those which are found in the glomerulosa, reticularis, and fasiculata of the adrenal cortex, in the renal arterioles and the juxtaglomerular cells of the kidney, and in the peripheral arterioles. Both peptides produced similar changes in the steriod secretion profiles for aldosterones, corticosterone, and cortisol in the dog. In the rat, both peptides similarly increased aldosterone and corticosterone secretion; however, a larger dose of the competitive antagonist Sar-1,Ala-8-angiotensin II was required to block the steroid response to the heptapeptide. This finding suggests that receptor affinity for des-Asp-1-angiotensin II may be greater than its affinity for angiotensin II. Both peptides also decreased renin secretion and renal blood flow similarly in the dog. The pressor response to the heptapeptide was only about one-half the pressor response to angiotensin II in both the rat and dog studies. Collectively, these observations in dogs and rats suggest that des-Asp-1-angiotensin II may mediate the response to the renin-angiotensin system at both adrenal and renal receptors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 178468     DOI: 10.1161/01.res.38.6.99

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  2 in total

1.  Autoradiographic localization of 3H-angiotensin II in rat adrenal glands.

Authors:  M Coutard; M J Osborne-Pellegrin
Journal:  Experientia       Date:  1980-02-15

2.  Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake.

Authors:  R M Carey; E D Vaughan; M J Peach; C R Ayers
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.